A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment
Latest Information Update: 19 Dec 2025
At a glance
- Drugs Tazemetostat (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Ipsen
Most Recent Events
- 19 Dec 2025 New trial record